Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL681102 | 0.99 | CETP (0.43) | CETP | |
| Hydrochloric Acid SCHEMBL681101 | 0.99 | CETP (0.43) | CETP | |
| SCHEMBL4827495 | 0.94 | CETP (0.43) | CETP | |
| SCHEMBL4824438 | 0.93 | CETP (0.39) | CETP | |
| Hydrochloric Acid SCHEMBL680175 | 0.93 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680176 | 0.93 | CETP (0.42) | CETP | |
| Hydrochloric Acid SCHEMBL680747 | 0.93 | CETP (0.39) | CETP | |
| Hydrochloric Acid SCHEMBL680748 | 0.93 | CETP (0.39) | CETP | |
| SCHEMBL4828879 | 0.92 | CETP (0.48) | CETP | |
| SCHEMBL20768084 | 0.92 | CETP (0.48) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828438-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase | BEND RESEARCH, INC. (US) | 2014-09-09 | — | — | US | claimed |
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | BEND RESEARCH, INC. (US) | 2009-05-07 | — | — | US | claimed |
| EP-1893178-A1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS | Pfizer Products Incorporated (US) | 2008-03-05 | — | — | EP | claimed |
| US-7332514-B2 | Dibenzylamine compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2008-02-19 | — | — | US | claimed |
| WO-2006129167-A1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| US-9724362-B2 | Pharmaceutical compositions comprising nanoparticles and a resuspending material | BEND RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9545384-B2 | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate | BEND RESEARCH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| EP-1844078-B1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | BEND RES INC (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2231169-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2162120-B1 | NANOPARTICLES COMPRISING A NON-IONIZABLE CELLULOSIC POLYMER AND AN AMPHIPHILIC NON-IONIZABLE BLOCK COPOLYMER | BEND RES INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9265731-B2 | Drying of drug-containing particles | BEND RESEARCH, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-1855652-B1 | DRYING OF DRUG-CONTAINING PARTICLES | BEND RES INC (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2006129167-A1 | PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006082500-A1 | DOSAGE FORMS PROVIDING CONTROLLED AND IMMEDIATE RELEASE OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND IMMEDIATE RELEASE OF HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082518-A1 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006079921-A2 | DRYING OF DRUG-CONTAINING PARTICLES | PFIZER PRODUCTS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006079922-A2 | FAST-DISINTEGRATING MICROPOROUS BINDER AND PROCESS FOR MAKING IT | PFIZER PRODUCTS INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006033002-A1 | 4-AMINO SUBSTITUTED-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | PFIZER INC | 2006-03-23 | — | — | US | disclosed |
| WO-2005115330-A2 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118328-A1 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase | CETP, HMGCR, MTTP | CETP 1/4885 |
| US-20060063803-A1 | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds | APOB, LDLR, CETP | CETP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.